top of page

Z1P in the news

Z1P in the news

April 2015

 

ZoneOne Pharma awarded NCI grant to retarget FDA-approved anticancer liposomal drugs to cancer stem cells.

 

Project number: 1R41CA192689-01

March 2015

 

ZoneOne Pharma awarded phase II NIH grant for twice weekly subcutaneous liposome chelator to treat transfusional iron overload.  

 

Project number: 2R44HD075429-02

September 2014

 

ZoneOne Pharma awarded FDA grant to develop evaluation of in vitro release methods for liposomal amphotericin B.

 

Project number: 1U01FD005249-01

September 2014

 

ZoneOne Pharma awarded FDA grant for the development of a liposome doxorubicin drug product release assay.

 

Project number: 3U01FD004893-01S1

July 2013

 

ZoneOne Pharma awarded phase 1 FDA grant for twice weekly subcutaneous liposome chelator to treat transfusional iron overload.

 

Project number: 1R43HD075429-01 

September 2012

 

ZoneOne Pharma awarded an National Cancer Institute contract to develop a liposomal Hsp90 inhibitor for cancer treatment

 

Project number: N43CO120082

Events & Presentations 

December 2016

 

The American Society of Hematology (ASH) 58th annual meeting 

 

San Diego, CA

June 30th-July 02, 2016

9th World Drug Delivery Summit, New Orleans, Louisiana

 

Dr. Noble will give an oral presentation on the L-DFO project entitled "Liposome Encapsulated Deferoxamine is a More Effective Iron Chelator than Desferal® in an Iron Overloaded Mouse Model"

bottom of page